Dale Muzzey's most recent trade in Myriad Genetics, Inc. was a trade of 942 Common Stock done at an average price of $8.1 . Disclosure was reported to the exchange on April 14, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Myriad Genetics, Inc. | Dale Muzzey | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.08 per share. | 14 Apr 2025 | 942 | 170,599 (0%) | 0% | 8.1 | 7,611 | Common Stock |
| Myriad Genetics, Inc. | Dale Muzzey | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.01 per share. | 22 Mar 2025 | 5,334 | 172,886 (0%) | 0% | 10.0 | 53,393 | Common Stock |
| Myriad Genetics, Inc. | Dale Muzzey | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.01 per share. | 22 Mar 2025 | 2,011 | 178,220 (0%) | 0% | 10.0 | 20,130 | Common Stock |
| Myriad Genetics, Inc. | Dale Muzzey | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.98 per share. | 22 Mar 2025 | 800 | 171,541 (0%) | 0% | 10.0 | 7,984 | Common Stock |
| Myriad Genetics, Inc. | Dale Muzzey | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.98 per share. | 22 Mar 2025 | 545 | 172,341 (0%) | 0% | 10.0 | 5,439 | Common Stock |
| Myriad Genetics, Inc. | Dale Muzzey | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2025 | 75,773 | 193,539 (0%) | 0% | 0 | Common Stock | |
| Myriad Genetics, Inc. | Dale Muzzey | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.07 per share. | 13 Mar 2025 | 8,544 | 184,995 (0%) | 0% | 10.1 | 86,038 | Common Stock |
| Myriad Genetics, Inc. | Dale Muzzey | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.07 per share. | 13 Mar 2025 | 4,764 | 180,231 (0%) | 0% | 10.1 | 47,973 | Common Stock |
| Myriad Genetics, Inc. | Dale Muzzey | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2025 | 10,622 | 117,766 (0%) | 0% | 0 | Common Stock | |
| Myriad Genetics, Inc. | Dale Muzzey | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.71 per share. | 01 Jan 2025 | 417 | 107,144 (0%) | 0% | 13.7 | 5,717 | Common Stock |
| Myriad Genetics, Inc. | Dale Muzzey | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.37 per share. | 09 Oct 2024 | 452 | 107,561 (0%) | 0% | 24.4 | 11,015 | Common Stock |
| Myriad Genetics, Inc. | Dale Muzzey | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 26.17 per share. | 11 Sep 2024 | 2,100 | 108,013 (0%) | 0% | 26.2 | 54,961 | Common Stock |
| Myriad Genetics, Inc. | Dale Muzzey | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.55 per share. | 14 Apr 2024 | 940 | 110,113 (0%) | 0% | 19.6 | 18,377 | Common Stock |
| Myriad Genetics, Inc. | Dale Muzzey | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.24 per share. | 22 Mar 2024 | 1,405 | 111,996 (0%) | 0% | 22.2 | 31,247 | Common Stock |
| Myriad Genetics, Inc. | Dale Muzzey | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.24 per share. | 22 Mar 2024 | 561 | 111,053 (0%) | 0% | 22.2 | 12,477 | Common Stock |
| Myriad Genetics, Inc. | Dale Muzzey | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.24 per share. | 22 Mar 2024 | 382 | 111,614 (0%) | 0% | 22.2 | 8,496 | Common Stock |
| Myriad Genetics, Inc. | Dale Muzzey | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2024 | 49,250 | 116,723 (0%) | 0% | 0 | Common Stock | |
| Myriad Genetics, Inc. | Dale Muzzey | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.16 per share. | 14 Mar 2024 | 3,322 | 113,401 (0%) | 0% | 21.2 | 70,294 | Common Stock |
| Myriad Genetics, Inc. | Dale Muzzey | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.14 per share. | 01 Jan 2024 | 303 | 67,473 (0%) | 0% | 19.1 | 5,799 | Common Stock |
| Myriad Genetics, Inc. | Dale Muzzey | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.27 per share. | 14 Apr 2023 | 638 | 68,217 (0%) | 0% | 22.3 | 14,208 | Common Stock |
| Myriad Genetics, Inc. | Dale Muzzey | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 23.72 per share. | 24 Mar 2023 | 545 | 68,855 (0%) | 0% | 23.7 | 12,927 | Common Stock |
| Myriad Genetics, Inc. | Dale Muzzey | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 23.72 per share. | 24 Mar 2023 | 372 | 69,400 (0%) | 0% | 23.7 | 8,824 | Common Stock |
| Myriad Genetics, Inc. | Dale Muzzey | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.91 per share. | 22 Mar 2023 | 1,399 | 69,772 (0%) | 0% | 22.9 | 32,051 | Common Stock |
| Myriad Genetics, Inc. | Dale Muzzey | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 28,459 | 71,171 (0%) | 0% | 0 | Common Stock | |
| Myriad Genetics, Inc. | Dale Muzzey | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.51 per share. | 01 Jan 2023 | 302 | 42,712 (0%) | 0% | 14.5 | 4,382 | Common Stock |
| Myriad Genetics, Inc. | Dale Muzzey | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.62 per share. | 09 Oct 2022 | 309 | 43,014 (0%) | 0% | 19.6 | 6,063 | Common Stock |
| Myriad Genetics, Inc. | Dale Muzzey | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.69 per share. | 25 Sep 2022 | 345 | 43,456 (0%) | 0% | 18.7 | 6,448 | Common Stock |
| Myriad Genetics, Inc. | Dale Muzzey | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.41 per share. | 25 Sep 2022 | 133 | 43,323 (0%) | 0% | 18.4 | 2,449 | Common Stock |